Brokerages Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) PT at $3.33

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) has been assigned an average rating of “Hold” from the five analysts that are presently covering the stock, Marketbeat reports. Four analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $3.33.

Separately, StockNews.com started coverage on Syros Pharmaceuticals in a research note on Monday, April 14th. They set a “sell” rating on the stock.

Hedge Funds Weigh In On Syros Pharmaceuticals

A hedge fund recently bought a new stake in Syros Pharmaceuticals stock. Two Sigma Securities LLC acquired a new stake in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 107,742 shares of the company’s stock, valued at approximately $25,000. Two Sigma Securities LLC owned about 0.40% of Syros Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 91.47% of the company’s stock.

Syros Pharmaceuticals Trading Up 34.5 %

SYRS stock opened at $0.03 on Friday. The stock has a market cap of $721,780.80, a P/E ratio of -0.01 and a beta of 1.31. Syros Pharmaceuticals has a twelve month low of $0.02 and a twelve month high of $6.93. The company’s 50 day moving average is $0.08 and its two-hundred day moving average is $0.59.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.